Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis
Open Access
- 2 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Advances in Rheumatology
- Vol. 61 (1), 1-13
- https://doi.org/10.1186/s42358-021-00202-7
Abstract
Objectives: To explore the risk factors for systemic lupus erythematosus (SLE) flare and their impact on prognosis. Methods: The clinical characteristics, laboratory results, and treatment plans of 121 patients with SLE flare were retrospectively analyzed. Ninety-eight SLE outpatients with sustained remission during the same period were selected as controls. Logistic multivariate regression analysis was employed to screen for risk factors for SLE flare. Results: Infection, thrombocytopenia, arthritis, anti-nucleosome antibodies positive, anti-β2-glycoprotein I (IgG) antibodies positive, and patient’s self-discontinuation of medicine maintenance therapy might be risk factors for SLE flare. Patients who discontinued medicine maintenance therapy by themselves had a significantly higher rate of severe SLE flare than patients with regular medicine maintenance therapy (P = 0.033). The incidence of anemia associated with SLE (P = 0.001), serositis (P = 0.005), and pulmonary hypertension (P = 0.003) in patients who discontinued medicine maintenance therapy were significantly higher than patients with regular medicine maintenance therapy. SLE patients with regular medicine maintenance therapy for less than 3 years had a higher risk of pulmonary hypertension than those with regular medicine maintenance therapy longer than 3 years (P = 0.034). Conclusions: The accompanying thrombocytopenia, arthritis, anti-nucleosome antibodies positive and anti-β2-glycoprotein I (IgG) antibodies positive at the onset of SLE may affect the prognosis of SLE. Patient’s self-discontinuation of medicine maintenance therapy is the main cause of SLE flare, which may induce severe flare in SLE patients and lead to a significantly higher incidence of pulmonary hypertension.Keywords
Funding Information
- Startup Fund for scientific research, Fujian Medical University (Grant No. 2017XQ1069)
- Fujian Youth Education Research Project (Grant No. JT180190)
This publication has 41 references indexed in Scilit:
- Anti‐β2‐glycoprotein I antibodiesAnnals of the New York Academy of Sciences, 2013
- Flare, Persistently Active Disease, and Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: A 2-Year Follow-Up StudyPLOS ONE, 2012
- A novel mechanism of thrombosis in antiphospholipid antibody syndromeJournal of Autoimmunity, 2010
- Systemic lupus erythematosus and tuberculosisJournal of Postgraduate Medicine, 2010
- Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han populationClinical Rheumatology, 2009
- Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosusArthritis & Rheumatism, 2006
- The nature and outcome of infection in systemic lupus erythematosusLupus, 2002
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992